Gossamer Bio is trading 10.61% down now at $0.18 as investors reassess dilution risk from its structured private placement.
- Financing includes pre-funded warrants priced at $0.1399 and up to $250 million in potential proceeds.
- Additional funding is tied to FDA milestones for seralutinib; the structure may increase future share supply, creating an overhang despite broader biotech strength.
- Trading is active during the August 26, 2026 regular session, reversing the prior session’s 16.86% gain.